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Inhibition of heparin-binding epidermal growth factor-like Abnormalities in podocyte function appear to be the
growth factor increases albuminuria in puromycin aminonu- most important contributors to massive proteinuria.
cleoside nephrosis. Areas of the glomerular basement membrane (GBM)
Background. Our previous work in the acute puromycin not covered by podocytes appear to be the major sitesaminonucleoside nephrosis (PAN) model has demonstrated
of protein loss in studies using tracers. The ultrastructuralup-regulation of heparin-binding epidermal growth factor-like
appearance of foot process effacement is also seen in allgrowth factor (HB-EGF) mRNA and protein within glomeru-
lar epithelial cells (GECs) prior to the onset of proteinuria. diseases causing nephrotic-range proteinuria, although
Methods. To determine whether increased HB-EGF expres- the importance of podocyte effacement in the genesis of
sion in the acute PAN model contributes to the pathogenesis proteinuria is not clear [1]. The most important adhesion
of proteinuria, a monoclonal antibody (DE10) was produced molecule involved in maintenance of normal podocyteagainst recombinant human HB-EGF.
morphology appears to be the b1-integrin, VLA-3 [2, 3].Results. The specificity of DE10 for human HB-EGF was
VLA-3 is also connected through a series of intracellularconfirmed by enzyme-linked immunosorbent assay, immuno-
molecules (for example, vinculin, paxilin, and talin) tohistochemical staining, and flow cytometry of transfected cells
expressing human and rat HB-EGF, and inhibition of cell pro- the cytoskeleton. Disruption of the connection between
liferation. DE10 also reacted with cells transfected with rat VLA-3 on the cell surface and F-actin microfilaments
HB-EGF cDNA. Administration of 0.5 mg affinity-purified inside the cell may be one mechanism by which foot
DE10 to normal rats did not cause significant albuminuria
process effacement occurs, a process suggested by studiescompared with controls. Five days after the induction of the
of VLA-3 knockout mice [4].acute PAN model, albuminuria was significantly greater in
VLA-3 has been shown to associate on the cell surfaceanimals treated with 0.5 mg DE10 than a control mAb (162.6 6
32.4 vs. 64.8 6 10.2 mg/day, respectively, P , 0.01). Rats treated with heparin-binding epidermal growth factor-like growth
with DE10 had an earlier onset of severe albuminuria, but no factor (HB-EGF) [5, 6]. Most normal glomeruli do not
increase in maximal albuminuria at later time points. Electron express HB-EGF mRNA or protein at levels detectable
microscopy showed marked podocyte effacement in both by in situ hybridization or immunohistochemistry [7–9].DE10-treated and control animals, but no obvious difference
Prior to the onset of proteinuria in the acute puromycinbetween groups. However, adhesion of the human GEC line
aminonucleoside nephrosis (PAN) and passive Heymann56/10 A1 to laminin and fibronectin, but not to collagens I or
IV, was reduced by DE10. nephritis models, however, HB-EGF mRNA and protein
Conclusions. This study suggests that HB-EGF contributes are easily detectable in podocytes [7]. In view of the close
to the integrity of the glomerular filtration barrier, particularly association between HB-EGF and VLA-3, it is possible
when the podocyte has been injured. Following podocyte in- that increased expression of HB-EGF could modify the
jury, adhesion to laminin in the glomerular basement mem-
function of VLA-3 in disease, influencing the onset ofbrane by HB-EGF may be important in reducing albuminuria.
proteinuria. In this study, therefore, we have produced a
mouse monoclonal antibody (mAb) against HB-EGF to
determine its role in the pathogenesis of acute proteinuria.Key words: HB-EGF, proteinuria, puromycin aminonucleoside, glo-
merular filtration barrier, VLA-3 adhesion molecule, F-actin microfil-
aments.
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nant human HB-EGF (R&D Systems, Minneapolis, MN, amine hydrochloride (OPD), and the reaction was
stopped with 4 N H2SO4. Plates were read on an auto-USA) emulsified in complete Freund’s adjuvant (day 0)
or incomplete Freund’s adjuvant (days 21 and 35) by mated plate reader (Behring EL 311 Microplate Reader;
Behring, Behringwerke, Germany) at optical densitiesintraperitoneal injection. Spleen cells were harvested
three days after the third immunization and were fused 490 and 630 nm.
with the nonsecreting mouse myeloma Sp2/0-Ag-14 using
Transfection of NIH-3T3, CHO, and Cos cellspolyethylene glycol according to a published method [10].
Fusions were plated in 96-well plates at about 100 cells To confirm mAb binding to rat and human HB-EGF,
cells were transfected with one of two constructs. pHB-per well, and hybridomas were selected in hypoxanthine-
aminopterin-thymidine (HAT). Wells containing hybrid- EGF.hu was prepared by subcloning a 630 bp fragment
of human HB-EGF cDNA (a generous gift from Dr. M.omas were screened by enzyme-linked immunosorbent
assay (ELISA; discussed later in this article) against re- Gagnon in Professor M. Klagsbrun’s Laboratory, Chil-
dren’s Hospital, Harvard Medical School, Boston, MA,combinant human HB-EGF. Positive wells were grown
to 20 mL and frozen in liquid nitrogen. Cloning was USA) encoding the entire 208 amino acids, including the
ATG start codon and the TGA stop codon. The fragmentperformed by limiting dilution in 96-well plates using
thymocyte feeders, as described by Oi and Herzenberg was subcloned into the expression vector pcDNA-3 (In-
vitrogen Corp., San Diego, CA, USA) to create the con-[11]. Antibody was used as spent hybridoma superna-
tants or purified ascitic fluid. Antibody subclass was struct pHB-EGF.hu. pHB-EGF.rat was produced by first
amplifying the coding sequence of rat HB-EGF using thedetermined by Ouchterlony immunodiffusion using a
commercial mouse mAb typing kit (The Binding Site, primers 59-ACCATGAAGCTGCTGCCGTC-39 and 59-
CATAGTCTGTTTGGCACTTAGAGGC-39 and sub-Birmingham, UK).
cloning this into pGEM-T (Pharmacia). The fragment
Production and purification of ascitic fluids was sequenced to confirm its identity, and the insert
was then excised and subcloned into pcDNA-3 to createFemale Balb/c mice aged five months or more were
used to produce ascitic fluids. 2,6,10,14-Tetramethylpen- pHB-EGF.rat.
For transfection, 2.2 3 105 cells/well were plated intotadecane (0.5 mL; Pristane; Sigma Chemical Co., St.
Louis, MO, USA) was injected intraperitoneally on two six-well tissue culture plates in 2 mL of complete media
in a CO2 incubator at 378C. Cells were incubated for 18occasions, seven days apart, followed by 1 to 5 3 106
hybridoma cells three days after the second injection. hours until 60% confluent. Two solutions were prepared:
2 mg of plasmid DNA were dissolved in 100 mL serum-Mice were inspected daily for abdominal swelling and
were sacrificed before there was evidence of distress. free medium (Opti-MEM 1 reduced serum medium),
and 12 mL of lipofectamine (Life Technologies, Gaithers-Ascitic fluids were collected by laparotomy, allowed to
clot overnight, and further purified by ammonium sulfate burg, MD, USA) were dissolved in 100 mL serum-free
medium. The two solutions were mixed gently and leftprecipitation. Thereafter, mouse IgG was purified by
affinity chromatography on a HiTrap protein G column at room temperature for 15 minutes; 0.8 mL of serum-
free DMEM was then added to the mixed solution and(Pharmacia Biotech, Uppsala, Sweden). The purified
mAb was dialyzed against phosphate-buffered saline overlaid onto washed cells for five hours at 378C in the
incubator. One milliliter of DMEM containing 20% fetal(PBS) prior to use. Purity of the affinity-purified mAb
was confirmed by sodium dodecyl sulfate-polyacryl- calf serum (FCS) was added, and the medium was re-
placed 24 hours later. For creation of stable transfectants,amide gel electrophoresis (SDS-PAGE).
cells were selected in G418 and assayed when stable cell
ELISA for the detection of antibodies against EGF lines emerged.
and related proteins
Immunohistochemical staining of a transfected cell lineEnzyme-linked immunosorbent assay (ELISA) was
performed as described by Engvall and Perlman [12]. NIH-3T3 cells were transiently transfected with pHB-
EGF.hu or vector control using lipofectamine as de-Briefly, flat-bottomed PVC plates (Dynatech Labora-
tories Ltd., VA, USA) were coated with recombinant hu- scribed earlier. The cells were stained with the mAb
DE10 using a three-step method. Briefly, the cells wereman HB-EGF, or the related proteins betacellulin (BTC),
amphiregulin (AR), EGF, and transforming growth fac- grown on cover slips and fixed in acetone for five minutes
at 48C. DE10 as culture supernatant was added and incu-tor-a (TGF-a), by overnight incubation with the protein
in carbonate buffer, pH 9.6. Plates were blocked with 1% bated for one hour at 378C followed by 30 minutes with
a secondary antibody, rabbit anti-mouse Ig (Dako, Car-bovine serum albumin (BSA)/PBS. Hybridoma superna-
tants were used undiluted. Antibody binding was detected pinteria, CA, USA) at 1:20 dilution and a further 30
minutes with APAAP complex (Dako) at 1:40 dilution.using anti-mouse immunoglobulin coupled to horseradish
peroxidase. Plates were developed using o-phenylenedi- The slides were then developed in alkaline phosphatase
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substrate solution (Sigma) for 20 minutes and counter- Sraer. Twenty-four–well tissue culture plates were
coated with the relevant protein through the addition ofstained with hematoxylin and Scott’s tap water.
100 mL of a 10 mg/mL solution and incubation for two
Coupling of mAb to fluorescein isothiocyanate hours at 378C. The following extracellular matrix constit-
uents were used; bovine collagen I (Vitrogen; CollagenDE10 was purified with a protein-G column prior
to conjugation. The antibody was dialyzed overnight Corporation, Palo Alto, CA, USA), mouse type IV colla-
gen IV (Life Technologies), human placental lamininagainst two to three changes of pH 9.5 carbonate/bicar-
bonate buffer (8.6 g NaCO3 and 17.2 g NaHCO3–1 L (Sigma), and bovine plasma fibronectin (ICN Biomedi-
cals Inc., Aurora, OH, USA). Nonspecific adhesion wasH2O). The concentration of the protein was measured
by optimal density at 280 nm, and 1 mg/mL of protein was blocked by incubating the plates in 1% bovine serum
albumin in PBS at 48C overnight. Cell monolayers wereused for conjugation. Fluorescein isothiocyanate (FITC)
was dissolved in dimethyl sulfoxide (DMSO) to 10 radiolabeled with 3H-thymidine (2.5 mCi/mL) overnight
and then briefly trypsinized. The cells were resuspendedmg/mL, and 100 mg were then added to the purified
mAb dropwise, with stirring. The reaction was allowed in RPMI media containing 1% fetal calf serum and incu-
bated with the monoclonal antibodies DE10, OX-34to proceed for two hours shielded from light. After conju-
gation, excess dye was removed by gel filtration on Seph- (Serotec Ltd., Kidlington, Oxford, UK), or anti-CD49c
(the a chain of VLA-3) antibody (11G5; Serotec) at 4adex G-25 (PD10 columns from Pharmacia) in PBS con-
taining 0.1% NaN3. The absorbance of each conjugate mg/mL for approximately 15 minutes. The radiolabeled
cells were then added to the wells at 1 3 105 cells/wellwas measured at 280 nm, and the conjugated antibody
was stored at 48C, protected from light. and then incubated at 378C for one hour to allow the
initial attachments to form. Unattached cells were re-
Flow cytometry moved by washing with PBS, and the attached cells were
solubilized in 1 mol/L NaOH. Incorporation of the 3H-Transfected cells were trypsinized and washed with
PBS before incubating with FITC-labeled DE10, no anti- thymidine was determined using a cell harvester and
liquid scintillation b-counter, as before. Results are ex-body, and an irrelevant FITC-conjugated antibody for
30 minutes on ice. After washing the cells with PBS, the pressed as the percentage of binding compared with the
no-antibody control.cells were resuspended in 400 mL of PBS and analyzed
using a flow cytometer (FACSCalibur; Becton Dickin-
The acute PAN modelson, Sunnyvale, CA, USA).
Acute PAN was induced in 150 to 170 g Sprague-
Cell proliferation assay Dawley rats using an established protocol [7] by a single
intravenous injection of 15 mg/100 g PAN (Sigma). AtTwo 3 104 NIH-3T3 cells were placed in each well
of 24-well tissue culture plates (Flow Laboratories, least six rats were used per group.
McLean, VA, USA) and allowed to adhere for 24 hours
Administration of mAb to ratsin 10% FCS in RPMI 1640. The cells were growth ar-
rested for 48 hours in RPMI 1640 and then incubated Male Sprague-Dawley rats (150 to 170 g) were injected
intravenously with a single dose of 0.5 mg of DE10, thewith one of the following recombinant human growth
factors; HB-EGF, EGF, BTC, AR, and TGF-a. Growth irrelevant mAb RMAC 8 (IgG2a), or saline. For rats with
PAN, the antibody was administered the day followingfactors were all used at 10 ng/mL. 3H-thymidine 3 mCi
(New England Nuclear, Boston, MA, USA) and the anti- injection of PAN. Urine was collected for 16 hours in
metabolic cages. Albuminuria was measured by radialbody test reagents at 1 mg/mL were also added at the
same time. Cultures were incubated for 24 hours at 378C immunodiffusion using commercial plates incorporating
an anti-rat albumin antibody (rat/mouse albumin NLin 5% CO2. The cell layers were then washed, harvested
with 200 mL NaOH, and harvested onto glass fiber filter RID plates; The Binding Site).
paper using a cell harvester (Inotech Cell Harvester Sys-
Detection of DE10 in the serum of normal ratstem; Inotech Biosystems International, Rockville, MD,
USA). The filter paper from each well harvested was Male Sprague-Dawley rats (N 5 3) weighing approxi-
mately 150 g were injected intravenously with 0.5 mgthen mixed with 50 mL liquid scintillant, and specific
activity was counted using a b counter (Packard Tri- DE10. Blood was collected at various times, and the
injected DE10 was detected in rat serum using ELISA.Carb 1600CA).
Briefly, plates were coated with 10 mg/mL goat anti-
Cell adhesion assays mouse Ig, blocked, and then reacted with diluted (1:400)
rat serum collected between days 0 and 35. NoninjectedCell adhesion assays were performed as described by
Chakravarti, Tam, and Chung using the human GEC rats were also included as controls. Plates were then
incubated with biotinylated swine anti-mouse Ig fol-line 56/10 A1 [13, 14], a generous gift of Professor J.D.
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lowed by Streptavidin peroxidase. Peroxidase labeling
was revealed using OPD. The reaction was stopped using
4 mol/L sulfuric acid and absorbances read at 492 nm
on an ELISA plate reader (Behring). Known concentra-
tions of the injected antibody were used to generate a
standard curve and the concentration of DE10 in rat
serum calculated.
Fluorescence microscopy
Following induction of the PAN model of proteinuria,
rats weighing approximately 150 g were injected intrave-
nously with 1.5 mL saline, RMAC 8 0.5 mg, or DE10
0.5 mg, and then were sacrificed three days later. Kidneys
were harvested and snap frozen in liquid nitrogen, and
4 mm cryostat sections were prepared and fixed in ice-
cold acetone for 10 minutes at 48C. The sections were Fig. 1. ELISA of hybridoma supernatant from DE10 against recombi-
nant human growth factors of the epidermal growth factor (EGF) fam-blocked in 3% BSA/5% rat serum/PBS for 30 minutes
ily. “Neg” is a well not coated with a growth factor.at room temperature and then stained using anti–WT-1
rabbit polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at a final concentration of 1
mg/mL. Sections were washed in PBS and then stained found to be IgG2a. In ELISA, DE10 was strongly posi-
with Oregon Green-conjugated goat anti-mouse anti- tive against rhHB-EGF but did not react with rhEGF,
body at a final concentration of 5 mg/mL (Molecular rhTGF-a, rhAR, or rhBTC (Fig. 1). Reactivity with HB-
Probes, Eugene, OR, USA) and Texas red–X conjugated EGF was confirmed by immunohistochemical staining
goat anti-rabbit antibody at a final concentration of 2 of NIH-3T3 cells transiently transfected with a construct
mg/mL (Molecular Probes). Sections were comprehen- containing human HB-EGF cDNA (pHB-EGF.hu) using
sively washed in PBS and then mounted with fluorescent the APAAP technique (Fig. 2). Cells transfected with a
mounting medium (Dako). Images were collected and vector control were negative. Moreover, FITC-conju-
generated on a confocal laser scanning microscope (Bio- gated DE10 also reacted in flow cytometry with CHO
Rad MRC 1024; Bio-Rad Microscopy Division, Hemel cells stably transfected with pHB-EGF.hu (Fig. 3A).
Hempstead, Herts, UK). DE10 also bound Cos cells stably transfected with a
construct encoding rat HB-EGF (pHB-EGF.rat) by flowTransmission electron microscopy
cytometry (Fig. 3B). In both of these assays, DE10 did
Tissue was immersion fixed in 2.5% glutaraldehyde not bind cells transfected with a vector control.
for two hours, postfixed in 1% osmium tetroxide, dehy-
drated in graded acetones, and embedded in Epon-Aral- Functional activity of DE10
dite. Sections (0.08 m) were cut and stained with uranyl
To determine whether DE10 inhibited the functionalacetate and lead citrate and examined in a Phillips CM12
activity of HB-EGF, DE10 or an irrelevant mAb of theelectron microscope.
same isotype was added to NIH-3T3 cells stimulated
with HB-EGF, EGF, TGF-a, AR, or BTC. Cell prolifer-Statistics
ation was measured by incorporation of 3H-thymidine.Statistics were performed using the Instat software
There was significant inhibition of cell proliferation whenpackage, version 2.01, from GraphPad Software. Multi-
the cells were treated with DE10 and stimulated withple comparisons were performed using analysis of vari-
HB-EGF, but not with an irrelevant mAb (Fig. 4). Also,ance (ANOVA), followed by the Tukey–Cramer multi-
DE10 had no effect when cells were stimulated withple comparison test. A P value ,0.05 was considered
other members of the EGF family. Interestingly, inhibi-significant.
tion of proliferation with DE10 was not complete, de-
spite an approximately tenfold molar excess.
RESULTS
Treatment of rats with DE10Production and characterization of mAb DE10
The serum half-life of DE10 in normal rats, followingA total of 1540 wells were screened and 77 positive
administration of 0.5 mg affinity-purified DE10, waswells obtained. The mAb DE10 was selected for cloning
eight days (Fig. 5). When administered to normal rats,because it was the only antibody that could be shown to
stain tissue sections by immunohistochemistry. It was DE10 did not produce significant albuminuria. When
Fig. 2. Immunohistochemical staining of NIH-
3T3 cells transiently transfected with a mam-
malian expression vector without an insert
(vector control, pcDNA-3; A) or a vector con-
taining a full-length cDNA for the coding re-
gion of human HB-EGF (pHB-EGF.hu; B).
The red stain is positive (APAAP method,
3100).
Fig. 3. FACS histograms of FITC-conjugated DE10 binding to (A) Chinese hamster ovary (CHO) cells stably transfected with pcDNA-3 (vector
control, green line) or pHB-EGF.hu (red line), and (B) Cos cells stably transfected with pcDNA-3 (green line) or pHB-EGF.rat (red line).
Fig. 7. Localization of DE10 within the glomerulus of PAN-treated rats. Rats treated with PAN were injected with saline (A), RMAC 8 (B), or
DE10 (C ) and sacrificed three days later. Kidney sections were stained for the presence of administered antibody (anti-mouse Ig; green fluorescence)
and for podocyte nuclei (WT1; red fluorescence). No green fluorescence is seen in rats injected with saline (A). Green fluorescence, predominantly
within the lumina of capillaries, is seen in rats injected with RMAC 8 (B). Areas of colocalization of antibody and podocyte resulted in the
accumulation of emission, which appeared as yellow and are indicated with arrows (C).
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Fig. 4. Cell proliferation assay, measured using 3H-thymidine incorpo-
ration, of NIH-3T3 cells stimulated with growth factors of the EGF
family or no growth factor (Neg; ). Cells were stimulated with 10
ng/mL of each growth factor and saline or mAbs DE10 (j) or RMAC 8
( ) added at 1 mg/mL. *P , 0.0001. The error bars are 11 SD.
Fig. 6. Treatment of rats with 0.5 mg DE10. (A) Rats injected with
DE10 the day after induction of the PAN model (that is, on day 1) and
studied at five-day intervals thereafter. (B) A second group of rats
studied daily over the first five days postinduction of the PAN model.
*P , 0.01. Symbols are rats treated with: (j) RMAC 8; (r) DE10; or
(m) receiving no treatment. The error bars are 11 SD.
mals were complement-depleted using cobra venom fac-
tor (CVF) administered on alternate days and then
treated with DE10 after induction of the PAN model,
as before. Complement depletion was checked prior to
administration of each dose by CH50 and was found toFig. 5. Serum levels of DE10 in normal rats following injection of
be complete. There was no difference in the onset ofDE10. Rats were injected with 0.5 mg DE10 (N 5 3), and the data
were fit to the curve of best fit using Microsoft Excel. The error bars proteinuria in animals receiving CVF, PAN, and DE10
are 11 SD. compared with animals receiving only PAN and DE10
(data not shown).
Localization of DE10 in the kidneys of treated rats byadministered the day following injection of PAN 15
laser scanning confocal microscopymg/kg, there was an earlier onset of proteinuria (Fig. 6),
commencing at day 3 compared with day 5 in the control Rats injected with PAN were treated on the following
day (day 1) with saline (Fig. 7A), the irrelevant mAbrats (Fig. 6B), and a significantly greater level of protein-
uria at day 5 (Fig. 6A). By day 10, this had fallen to RMAC 8 (Fig. 7B), or DE10 (Fig. 7C), and sacrificed
on day 4. Antibody detected in kidney sections were stainedlevels comparable with control animals. When DE10 was
administered at day 5, however, there was no difference with anti-mouse Ig and the sections were costained with a
rabbit polyclonal antibody directed against the podocytein proteinuria five days later (data not shown). To deter-
mine whether the increase in proteinuria was due to marker WT1. Mouse Ig staining, in rats injected with
RMAC 8, was localized predominantly to capillary loopscomplement-mediated injury to podocytes by DE10, ani-
Khong et al: Inhibiting HB-EGF worsens proteinuria1104
(Fig. 7B). The same staining was seen in rats injected We have previously described an increase in HB-EGF
mRNA and protein in glomerular epithelial cells (GECs)with DE10, but in addition, there were cells that stained
prior to the onset of proteinuria in both PAN and passivewith both WT1 and anti-mouse Ig (Fig. 7C), demonstra-
Heymann nephritis [7]. The function of increased HB-ting that DE10 localized specifically to podocytes.
EGF in this location is unknown, but we proposed that
Electron microscopy of kidneys from rats treated it might contribute to the onset of proteinuria, either
with DE10 through stimulation of abortive mitogenesis of GEC with
subsequent detachment from the GBM or binding ofTo determine whether the severity of proteinuria at
HB-EGF to the GBM, so altering its filtration properties.day 5 was reflected by a difference in morphology, groups
Therefore, it was surprising that administration of DE10of three animals with PAN, which received either RMAC
increased proteinuria early in the course of the PAN8 or DE10 at day 1 postinduction, were killed at days 3
model, suggesting that up-regulation of HB-EGF wasand 5, and the kidneys were fixed for electron micros-
acting to decrease proteinuria. The findings did not ap-copy. The appearances of the kidney at day 3 were similar
pear to be due to complement-mediated injury to GECin both groups, although focal foot process effacement
because administration of cobra-venom factor did notand mild swelling of podocytes were only apparent in the
affect the result. There are at least three potential expla-animals that received DE10; the animals that received
nations for these observations.RMAC 8 showed relatively normal glomerular morphol-
First, there is evidence that the recirculation of albu-ogy at this stage (Fig. 8 A, B). However, at day 5, both
min in the glomerular filtrate through the proximal tu-groups showed widespread severe effacement of foot
bule may be considerable. It has been estimated that 1.8processes, associated with extensive swelling, vacuola-
mg/min of albumin per rat kidney may recirculate in thistion and protein droplet accumulation within the cyto-
way (abstract; Eppel et al, J Am Soc Nephrol 9:337A,plasm of podocytes (Fig. 8 C, D). There was no apparent
1998). It is possible that blocking HB-EGF interferesdifference between those animals administered RMAC 8
with this pathway. However, this appears an unlikelyand no evidence of podocyte detachment from the glo-
explanation, because administration of DE10 had nomerular basement membrane in either group.
effect on the level of proteinuria in the PAN model when
Inhibition of cell adhesion using DE10 administered at day 5 after induction. If the pathway
was blocked, then this should increase proteinuria irre-Adhesion of 56/10 A1 cells to laminin and fibronectin
spective of the time of administration.was significantly inhibited by DE10 (Fig. 9), but binding
A second potential explanation relies on the ability ofto collagen I and collagen IV was not affected. Inhibition
the transmembrane form of HB-EGF to inhibit apopto-of binding with the positive control mAb against the
sis in epithelial cells. This observation was made by Ta-a-subunit of VLA-3 (CD49c) was as predicted from pub-
kemura et al in the renal tubular epithelial cell line NRKlished specificity of VLA-3. The only difference between
52E [15]. Since so-called “bare areas” of the GBM areDE10 and the mAb against VLA-3 was the inability of
the reported to be the site of greatest passage of tracerDE10 to inhibit binding to collagen I.
molecules in PAN [16, 17], up-regulation of HB-EGF
may prevent detachment of GEC because of cell injury,
DISCUSSION and thus reduce the bare areas. This explanation appears
The mAb DE10 was made against recombinant human unlikely because we did not observe an increase in bare
HB-EGF. It was found to be specific for human HB- areas of the GBM in rats treated with DE10 compared
EGF by ELISA, and reactivity with cells transfected with with controls, although these could be distributed in a
expression constructs for both human and rat HB-EGF focal manner.
cDNA. The antibody also inhibited function of recombi- Finally, HB-EGF has been reported to associate with
nant human HB-EGF, as assessed by inhibition of cell the integrin VLA-3 on the surface of various cell types.
VLA-3 is the major integrin present on human GEC inproliferation.
c
Fig. 8. Electron microscopic examination of kidney tissue from rats at day 3 of the PAN model. (A) A kidney section from a rat administered
RMAC 8 shows relatively normal glomerular morphology with well-preserved foot processes. (B) A kidney section from a rat treated with DE10
shows focal foot process effacement (arrows), and a mild swelling of podocytes (p), which contain prominent endoplasmic reticulum. Electron
microscopic examination of kidney tissue from rats at day 5 of the PAN model. (C ) A kidney section from a rat administered RMAC 8 shows
widespread effacement of foot processes (arrows) associated with swelling, vacuolation (v), and protein droplet accumulation (*) within the
cytoplasm of podocytes. (D) A kidney from a rat treated with DE10 shows similar appearances to those seen in (C) with foot process effacement
(arrows), vacuolation (v), and protein droplet accumulation (*) within podocytes. Abbreviations are: C, glomerular capillary lumen; m, mesangial
cell. Magnification 37800.
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Fig. 9. Inhibition of adhesion of the human glomerular epithelial cell line 56/10 A1 to extracellular matrix constituents using monoclonal antibodies.
Lane A represents wells coated with BSA in each panel. Lanes B–E were coated with collagen IV, collagen I, laminin, or fibronectin as indicated.
Wells labeled B were treated with no mAb, well C with DE10 (anti-HB-EGF), well D with 11G5 (anti-CD49c), and well E with Ox34 as an
isotype-matched irrelevant control. All panels show representative results of three to six separate experiments. *P , 0.005; **P , 0.001.
vivo, and there is increasing evidence that it is important EGF to increase cell survival in response to pro-apo-
ptotic stimuli [15] or the adhesive properties of HB-EGF,in maintaining podocyte morphology through its con-
tacts with actin microfilaments inside the cell. The func- demonstrated in this article. Although the albuminuria
observed in response to injection of DE10 in normaltion of the interaction between HB-EGF and VLA-3 is
presently unknown. However, it is possible that HB- glomeruli was minimal, it suggests that HB-EGF also
has a role in maintaining the filtration barrier in normalEGF modifies the adhesive properties of VLA-3 and
helps to maintain podocyte morphology. In these studies, glomeruli.
Finally, DE10 is the first mAb reported against HB-the adhesive role of HB-EGF is further strengthened
EGF. Its ability to bind both human and rat HB-EGFby the demonstration that the inhibitory mAb DE10
and to inhibit function suggests that it may be a usefulreduced adhesion of the GEC line 56/10 A1 to fibronec-
reagent in defining the role of HB-EGF in kidney dis-tin and laminin. Despite this finding in vitro, however,
eases and other conditions, such as atherosclerosis,we were unable to demonstrate any difference in mor-
wound healing, and cancer, where it has been identifiedphology between animals treated with DE10 or control
as a potentially important growth factor.antibody.
The albuminuria that occurred after administration of
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